Phase III clinical trials of the cell differentiation agent-2 (CDA-2): Therapeutic efficacy on breast cancer, non-small cell lung cancer and primary hepatoma1
- Fengyi Feng,
- Qing Li,
- Changquan Ling,
- Yang Zhang,
- Fengzhan Qin,
- Huaqing Wang,
- Wenxia Huang,
- Shunchang Jiao,
- Qiang Chen,
- Mingzhong Li,
- Yunzhong Zhu,
- Meizhen Zhou,
- Jun Ren,
- Yetao Gao,
- Jingpo Zhao,
- Rongsheng Zheng,
- Wenhua Zhao,
- Zhiqiang Meng,
- Fang Li,
- Qizhong Zhang,
- Dongli Zhao,
- Liyan Xu,
- Yongqiang Zhang,
- Yanjun Zhang,
- Zhenjiu Wang,
- Shuanqi Liu,
- Ming C. Liau
- … show all 27 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The objective of this study was to explore the effect of CDA-2, a selective inhibitor of abnormal methylation enzymes in cancer cells, on the therapeutic efficacy of cytotoxic chemotherapy.
Advanced cancer patients, all of whom had previously undergone chemotherapy, were randomly divided into 2 groups, one receiving chemotherapy only as the control group, and the other receiving CDA-2 in addition to chemotherapy as the combination group. The therapeutic efficacies and the toxic manifestations of the 2 groups were compared based on the WHO criteria.
Of 454 cancer patients enrolled in phase III clinical trials of CDA-2, 80, 188, and 186 were breast cancer, NSCLC, and primary hepatoma patients, respectively. Among them 378 patients completed treatments according to the protocols. The results showed that the overall effective rate of the combination group was 2.6 fold that of the control group, 4.8 fold in the case of breast cancer, 2.3 fold in the case of primary hepatoma, and 2.2 fold in the case of NSCLC. Surprisingly, the combination therapy appeared to work better for stage IV than stage III patients. CDA-2 did not contribute additional toxicity. On the contrary, it reduced toxic manifestations of chemotherapy, particularly regarding white blood cells, nausea and vomiting.
Modulation of abnormal methylation enzymes by CDA-2 is definitely helpful to supplement chemotherapy. It significantly increased the therapeutic efficacy and reduced the toxic manifestation of cytotoxic chemotherapy on breast cancer and NSCLC.
Sponsered by Everlife Pharmaceutical Company of Hefei, Anhui, 231202, China.
Zochbauer-Muller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61:249–255.PubMed
Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–3229.PubMed
Paz MF, Fraga MF, Avila S, et al. A systemic profile of DNA methylation in human cancer cell lines. Cancer Res. 2003; 63:1114–1121.PubMed
Liau MC, Lee SS, Burzynski SR. Hypomethylation of nucleic acids: a key to the induction of terminal differentiation. Intl J Exp Clin Chemother. 1989;2:187–199.
Lotem J, Sachs L. Epigenetics wins over genetics: induction of differentiation in tumor cells. Seminars Cancer Biol. 2002; 12:339–346.CrossRef
Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. 2003;63:7089–7093.PubMed
Zhu WG, Otterson GA. The interaction of histone deacetylase inhibitions and DNA methyltransferase inhibitons in the treatment of human cancer cells. Curr Med Chem Anti-cancer Agents. 2003;3:187–199.CrossRef
Lin CH, Hsieh SY, Sheen IS, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res. 2001;61:4238–4243.PubMed
Gandet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science. 2003;300:489–492.CrossRef
Nishiagki M, Aoyagi K, Danjoh I, et al. Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. Cancer Res. 2005; 65:2115–2124.CrossRef
Liau MC, Chang CF, Becker FF. Alteration of S-adenosylmethionine synthetases during chemical hepato-carcinogenesis and in resulting carcinomas. Cancer Res. 1979; 39: 2113–2119.PubMed
Liau MC, Chang CF, Giovanella BC. Demonstratron of an altered S-adenosylmethionine synthetase in human malignant tumors xenografted into athymic nude mice. J Natl Cancer Inst. 1980; 64:1071–1075.PubMed
Liau MC, Burzynski SR. Altered methylation complex isozymes as selective targets for cancer chemotherapy. Drugs Exp Clin Res. 1986;12(Suppl.l):77–86.PubMed
Liau MC. Abnormal methylation enzymes: a selective molecular target for differentiation therapy of cancer. Chin Pharm J. 2004; 56: 57–67.
Salem C, Liang G, Tsai YC, et al. Progressive increase in de novo methylation of CpG islands in bladder cancer. Cancer Res. 2000; 60:2473–2476.PubMed
Eads CA, Lord RV, Wickramasingle U, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 2001; 61:3410–3418.PubMed
Kishi K, Doki Y, Yano M, et al. Reduced hMLHl expression after chemotherapy is an indicator for poor prognosis in esophageal cancers. Clin Cancer Res. 2003;9:4368–4375.PubMed
Nyce J. Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res. 1989;49:5829–5836.PubMed
Liau MC, Luong Y, Liau CP, et al. Prevention of drug induced DNA hypermethylation by antineoplaston components. Intl J Exp Clin Chemother. 1992;5:19–27.
Liau MC, Lee SS, Burzynski SR. Modulation of cancer methylation complex isozymes as a decisive factor in the induction of terminal differentiation mediated by Antineoplaston A5. Intl J Tiss React 1990;12(Suppl.l):27–36.
Liau MC, Huang LJ, Lee JH, et al. Development of differentiation helper inducers for the differentiation therapy of cancer. Chin Pharm J. 1998;50:289–303.
Liau MC, Liau CP. Methyltransferase inhibitors as excellent differentiation helper inducers for differentiation therapy of cancer. Bull Chin Cancer. 2002;11:166–168.
Liau MC, Szopa M, Burzynski B, et al. Chemo-surveillance: a novel concept of natural defense mechanism against cancer. Drugs Exp Clin Res. 1987;13:(Suppl.l): 77–82.
Liu YK, Li Y, Ma X, et al. Regulation of liver cancer related genes and alpha fetal protein expression by CDA -2. Bull Chin Cancer. 2002;11:169–172.
Sun JJ, Zhou XD, Liu YK, et al. Prevention of metastasis and recurrence in xenografted nude mice by differentiation inducer CDA-2. Chin Hepatobill J. 1999;5:14–16.
Xu JY, Zhou Q, Lu P, et al. Induction of apoptosis and reversal of drug resistance in human tumor cell line KBv200 by cell differentiation agent-2 (CDA-2). Chin J Intern Med. 2000;39:37–39.
Liao SK. Abrogation of telomerese activity by CDA-2. In: Liau MC. Smart Anticancer Drug CDA-2. Taipei, Taiwan: Shymou Publishing Co. 1999;188–190.
Meng ZQ, Huang, WX, Wang ZJ. Phase II clinical trial of CDA-2 on breast cancer. Bull Chin Cancer. 2002;11:113–114.
Gao YT, Shi SQ, Gu FL, et al. The effect of CDA -2 on advanced liver cancer in 15 cases. Bull Chin Cancer. 2002; 11:110–112.
Feng FY, Li Q, Wang ZJ. Effect of uroacitides in improving quality of life of advanced cancer patients. Chin J Clin Rehab. 2004;8:384–385.
Chen ZS, Ni M, Cheng HH, et al. Therapeutic efficacy of CDA-2 on advanced cancer patients: a comparison with cytotoxic chemotherapy. Chin J Clin Oncol Rehab. 1999;6:84–87.
Lai TY, Wu YW, Lin WC. Effect of an urinary preparation on acute liver injury induced by carbon tetrachloride. Chin Pharm J. 1998; 50:175–187.
Yen A. Control of HL -60 myeloid differentiation: evidence of uncoupled growth and differentiation, S-phase specificity, and two step regulation. Exp Cell Res. 1995;156:198–203.CrossRef
Castro-Munezledo F, Beltran-Langarice K, Kuri-Harcnch W. Commitemt of 3T3 -F442A cells to adipocyte differentiation takes place during the first 24–34h after adipogenic stimulation: TNF inhibits commitemt. Exp Cell Res. 2003;284:161–170.CrossRef
- Phase III clinical trials of the cell differentiation agent-2 (CDA-2): Therapeutic efficacy on breast cancer, non-small cell lung cancer and primary hepatoma1
Chinese Journal of Clinical Oncology
Volume 2, Issue 4 , pp 706-716
- Cover Date
- Print ISSN
- Online ISSN
- Chinese Anti-Cancer Association
- Additional Links
- abnormal methylation enzymes
- DNA hypomethylation
- differentiation therapy
- adjuvant chemotherapy
- Fengyi Feng (1)
- Qing Li (1)
- Changquan Ling (2)
- Yang Zhang (3)
- Fengzhan Qin (4)
- Huaqing Wang (5)
- Wenxia Huang (6)
- Shunchang Jiao (7)
- Qiang Chen (8)
- Mingzhong Li (9)
- Yunzhong Zhu (10)
- Meizhen Zhou (11)
- Jun Ren (12)
- Yetao Gao (2)
- Jingpo Zhao (3)
- Rongsheng Zheng (4)
- Wenhua Zhao (5)
- Zhiqiang Meng (6)
- Fang Li (7)
- Qizhong Zhang (8)
- Dongli Zhao (9)
- Liyan Xu (10)
- Yongqiang Zhang (11)
- Yanjun Zhang (12)
- Zhenjiu Wang (13)
- Shuanqi Liu (13)
- Ming C. Liau (14)
- Author Affiliations
- 1. The Cancer Hospital of the Chinese Academy of Medical Science, 100021, Beijing, China
- 2. Changhai Hospital of the Second Army Medical University, 200433, Shanghai, China
- 3. The Second Affiliated Hospital of Dalian Medical University, 116027, Dalian, China
- 4. The Cancer Hospital of Bengbu Medical College, 233004, Bengbu, China
- 5. The Cancer Hospital of Tianjin Medical University, 300060, Tianjin, China
- 6. The Affiliated Cancer Hospital of Fudan Medical University, 200032, Shanghai, China
- 7. The General Hospitalof PLA, 100835, Beijing, China
- 8. The Cancer Hospital of Fujian Province, 350014, Fuzhou, China
- 9. The First Affiliated Hospital of Xi’an Communication University, 710061, Xi’an, China
- 10. Beijing Chest Cancer Hospital, 101149, Beijing, China
- 11. Department of Health Beijing Hospital, 100730, Beijing, China
- 12. Xijing Hospital of the Fourth Military Medical University, 710033, Xi’an, China
- 13. Everlife Pharmaceutical Company, 231202, Hefei, China
- 14. Institute of Pharmaceutical Chemistry, China Medical University, Taichung 404, Taiwan